中国医药指南
中國醫藥指南
중국의약지남
CHINA MEDICINE GUIDE
2014年
10期
23-24
,共2页
短暂性脑缺血%阿托伐他汀%超敏C反应蛋白%脂蛋白相关磷脂酶A2
短暫性腦缺血%阿託伐他汀%超敏C反應蛋白%脂蛋白相關燐脂酶A2
단잠성뇌결혈%아탁벌타정%초민C반응단백%지단백상관린지매A2
Transient ischemic attack%Atorvastatin%hs-CRP%Lp-PLA2
目的:探讨阿托伐他汀对短暂脑缺血患者血浆超敏C反应蛋白和脂蛋白相关磷脂酶A2的影响。方法68例短暂脑缺血患者随机分为两组,对照组33例,治疗组35例;对照组采用常规治疗,治疗组在常规治疗的基础上加用阿托伐他汀20 mg,1次/天,口服,两组共治疗30 d。治疗前后测定患者血浆超敏C反应蛋白(hs-CRP)和脂蛋白相关磷脂酶A2(Lp-PLA2)的浓度。结果两组治疗后均明显降低血浆hs-CRP和LP-PLA2的表达,并且治疗组降低二者更明显(P<0.05)。两组均未出现严重的不良反应。结论阿托伐他汀可以明显降低短暂脑缺血患者血浆hs-CRP和Lp-PIA2的表达。
目的:探討阿託伐他汀對短暫腦缺血患者血漿超敏C反應蛋白和脂蛋白相關燐脂酶A2的影響。方法68例短暫腦缺血患者隨機分為兩組,對照組33例,治療組35例;對照組採用常規治療,治療組在常規治療的基礎上加用阿託伐他汀20 mg,1次/天,口服,兩組共治療30 d。治療前後測定患者血漿超敏C反應蛋白(hs-CRP)和脂蛋白相關燐脂酶A2(Lp-PLA2)的濃度。結果兩組治療後均明顯降低血漿hs-CRP和LP-PLA2的錶達,併且治療組降低二者更明顯(P<0.05)。兩組均未齣現嚴重的不良反應。結論阿託伐他汀可以明顯降低短暫腦缺血患者血漿hs-CRP和Lp-PIA2的錶達。
목적:탐토아탁벌타정대단잠뇌결혈환자혈장초민C반응단백화지단백상관린지매A2적영향。방법68례단잠뇌결혈환자수궤분위량조,대조조33례,치료조35례;대조조채용상규치료,치료조재상규치료적기출상가용아탁벌타정20 mg,1차/천,구복,량조공치료30 d。치료전후측정환자혈장초민C반응단백(hs-CRP)화지단백상관린지매A2(Lp-PLA2)적농도。결과량조치료후균명현강저혈장hs-CRP화LP-PLA2적표체,병차치료조강저이자경명현(P<0.05)。량조균미출현엄중적불량반응。결론아탁벌타정가이명현강저단잠뇌결혈환자혈장hs-CRP화Lp-PIA2적표체。
Objective To study the effectiveness of atorvastatin on high sensitivity c-reactive protein (hs-CRP) and lipoprotein-associated phospholipaseA2(Lp-PLA2) in the serum of patients with transient ischemic attack. Methods Sixty-Eight patients with Transient ischemic attack were randomly divided into two groups. The control group(n=33 cases) and the treatment group(n=35 cases).The paitents in the control group were treated through the conventional. Treatment and the patients in the treatment group were treated thorough atorvastatin plus the conventional treatment. Atorvastatin was used through orally 20mg once daily. The hs-CRP and Lp-PLA2 were detected before and after treatment. Results The hs-CRP and Lp-PLA2 in serum of patients were decreased after treatment. The re was a significant difference between two groups(P<0.05). There were not any serious adverse events in the both groups. Conclusion Atorvastatin can significantly decrease hs-CRP and Lp-PLA2 in the serum of patients with transient ischemic attack.